FTSE MIB
34.657,35 +318,03 (+0,93%) Dow Jones
39.512,84 +125,08 (+0,32%) Nasdaq
16.340,87 -5,40 (-0,03%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
78,20 -1,06 (-1,34%) Bitcoin EUR
56.402,11 -1.889,43 (-3,24%)
AbbVie Inc (4AB.BE)
| Chiusura precedente | 149,16 |
| Aperto | 148,82 |
| Denaro | 148,42 x 0 |
| Lettera | 150,22 x 0 |
| Min-Max giorno | 148,80 - 149,82 |
| Intervallo di 52 settimane | 119,00 - 168,52 |
| Volume | |
| Media Volume | 5 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 25 lug 2024 - 29 lug 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAlector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
Data readout expected in Q4 2024SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). Data from the trial are expected in the fourth quarter of 2024. AL00
GlobeNewswireKineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to its Board of Directors. Ms. Drapkin will join the company’s audit and compensation committees and Dr. Dylla will join the compensation committee. “Kim and Scott’s extensive strategic, financial and clinical expertis
